表皮水疱症治療薬の世界市場規模・現状・予測2021年-2027年

QYResearchが発行した調査報告書(QY21JNE2197)
◆英語タイトル:Global Epidermolysis Bullosa Therapeutics Market Size, Status and Forecast 2021-2027
◆商品コード:QY21JNE2197
◆発行会社(リサーチ会社):QYResearch
◆発行日:2021年6月(※2024年版があります。お問い合わせください。)
◆ページ数:108
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査資料では、表皮水疱症治療薬の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(EB-201、FCX-007、ICX-RHY、INM-750、その他)、用途別市場規模(診療所、病院、その他)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・表皮水疱症治療薬の市場動向
・企業の競争状況、市場シェア
・表皮水疱症治療薬の種類別市場規模(EB-201、FCX-007、ICX-RHY、INM-750、その他)
・表皮水疱症治療薬の用途別市場規模(診療所、病院、その他)
・表皮水疱症治療薬の北米市場規模2016-2027(アメリカ、カナダ)
・表皮水疱症治療薬の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・表皮水疱症治療薬のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・表皮水疱症治療薬の中南米市場規模2016-2027(メキシコ、ブラジル)
・表皮水疱症治療薬の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(Birken AG、Fibrocell Science, Inc.、GlaxoSmithKline Plc、InMed Pharmaceuticals Inc.、Karus Therapeutics Limited、ProQR Therapeutics N.V.、RegeneRx Biopharmaceuticals, Inc.、Scioderm, Inc.、Stratatech Corporation、TWi Pharmaceuticals, Inc.、WAVE Life Sciences Ltd.)
・結論
【レポートの概要】

Market Analysis and Insights: Global Epidermolysis Bullosa Therapeutics Market
The global Epidermolysis Bullosa Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Epidermolysis Bullosa Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Epidermolysis Bullosa Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Epidermolysis Bullosa Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Epidermolysis Bullosa Therapeutics market.

Global Epidermolysis Bullosa Therapeutics Scope and Market Size
Epidermolysis Bullosa Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Epidermolysis Bullosa Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
EB-201
FCX-007
ICX-RHY
INM-750
Others

Segment by Application
Clinic
Hospital
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Birken AG
Fibrocell Science, Inc.
GlaxoSmithKline Plc
InMed Pharmaceuticals Inc.
Karus Therapeutics Limited
ProQR Therapeutics N.V.
RegeneRx Biopharmaceuticals, Inc.
Scioderm, Inc.
Stratatech Corporation
TWi Pharmaceuticals, Inc.
WAVE Life Sciences Ltd.

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Epidermolysis Bullosa Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 EB-201
1.2.3 FCX-007
1.2.4 ICX-RHY
1.2.5 INM-750
1.2.6 Others
1.3 Market by Application
1.3.1 Global Epidermolysis Bullosa Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Epidermolysis Bullosa Therapeutics Market Perspective (2016-2027)
2.2 Epidermolysis Bullosa Therapeutics Growth Trends by Regions
2.2.1 Epidermolysis Bullosa Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Epidermolysis Bullosa Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Epidermolysis Bullosa Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Epidermolysis Bullosa Therapeutics Industry Dynamic
2.3.1 Epidermolysis Bullosa Therapeutics Market Trends
2.3.2 Epidermolysis Bullosa Therapeutics Market Drivers
2.3.3 Epidermolysis Bullosa Therapeutics Market Challenges
2.3.4 Epidermolysis Bullosa Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Epidermolysis Bullosa Therapeutics Players by Revenue
3.1.1 Global Top Epidermolysis Bullosa Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Epidermolysis Bullosa Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Epidermolysis Bullosa Therapeutics Revenue
3.4 Global Epidermolysis Bullosa Therapeutics Market Concentration Ratio
3.4.1 Global Epidermolysis Bullosa Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Epidermolysis Bullosa Therapeutics Revenue in 2020
3.5 Epidermolysis Bullosa Therapeutics Key Players Head office and Area Served
3.6 Key Players Epidermolysis Bullosa Therapeutics Product Solution and Service
3.7 Date of Enter into Epidermolysis Bullosa Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Epidermolysis Bullosa Therapeutics Breakdown Data by Type
4.1 Global Epidermolysis Bullosa Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Epidermolysis Bullosa Therapeutics Forecasted Market Size by Type (2022-2027)

5 Epidermolysis Bullosa Therapeutics Breakdown Data by Application
5.1 Global Epidermolysis Bullosa Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Epidermolysis Bullosa Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Epidermolysis Bullosa Therapeutics Market Size (2016-2027)
6.2 North America Epidermolysis Bullosa Therapeutics Market Size by Type
6.2.1 North America Epidermolysis Bullosa Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Epidermolysis Bullosa Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Epidermolysis Bullosa Therapeutics Market Size by Type (2016-2027)
6.3 North America Epidermolysis Bullosa Therapeutics Market Size by Application
6.3.1 North America Epidermolysis Bullosa Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Epidermolysis Bullosa Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Epidermolysis Bullosa Therapeutics Market Size by Application (2016-2027)
6.4 North America Epidermolysis Bullosa Therapeutics Market Size by Country
6.4.1 North America Epidermolysis Bullosa Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Epidermolysis Bullosa Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Epidermolysis Bullosa Therapeutics Market Size (2016-2027)
7.2 Europe Epidermolysis Bullosa Therapeutics Market Size by Type
7.2.1 Europe Epidermolysis Bullosa Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Epidermolysis Bullosa Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Epidermolysis Bullosa Therapeutics Market Size by Type (2016-2027)
7.3 Europe Epidermolysis Bullosa Therapeutics Market Size by Application
7.3.1 Europe Epidermolysis Bullosa Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Epidermolysis Bullosa Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Epidermolysis Bullosa Therapeutics Market Size by Application (2016-2027)
7.4 Europe Epidermolysis Bullosa Therapeutics Market Size by Country
7.4.1 Europe Epidermolysis Bullosa Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Epidermolysis Bullosa Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Type
8.2.1 Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Application
8.3.1 Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Region
8.4.1 Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Epidermolysis Bullosa Therapeutics Market Size (2016-2027)
9.2 Latin America Epidermolysis Bullosa Therapeutics Market Size by Type
9.2.1 Latin America Epidermolysis Bullosa Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Epidermolysis Bullosa Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Epidermolysis Bullosa Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Epidermolysis Bullosa Therapeutics Market Size by Application
9.3.1 Latin America Epidermolysis Bullosa Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Epidermolysis Bullosa Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Epidermolysis Bullosa Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Epidermolysis Bullosa Therapeutics Market Size by Country
9.4.1 Latin America Epidermolysis Bullosa Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Epidermolysis Bullosa Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size by Type
10.2.1 Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size by Application
10.3.1 Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size by Country
10.4.1 Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Birken AG
11.1.1 Birken AG Company Details
11.1.2 Birken AG Business Overview
11.1.3 Birken AG Epidermolysis Bullosa Therapeutics Introduction
11.1.4 Birken AG Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021)
11.1.5 Birken AG Recent Development
11.2 Fibrocell Science, Inc.
11.2.1 Fibrocell Science, Inc. Company Details
11.2.2 Fibrocell Science, Inc. Business Overview
11.2.3 Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Introduction
11.2.4 Fibrocell Science, Inc. Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021)
11.2.5 Fibrocell Science, Inc. Recent Development
11.3 GlaxoSmithKline Plc
11.3.1 GlaxoSmithKline Plc Company Details
11.3.2 GlaxoSmithKline Plc Business Overview
11.3.3 GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Introduction
11.3.4 GlaxoSmithKline Plc Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021)
11.3.5 GlaxoSmithKline Plc Recent Development
11.4 InMed Pharmaceuticals Inc.
11.4.1 InMed Pharmaceuticals Inc. Company Details
11.4.2 InMed Pharmaceuticals Inc. Business Overview
11.4.3 InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Introduction
11.4.4 InMed Pharmaceuticals Inc. Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021)
11.4.5 InMed Pharmaceuticals Inc. Recent Development
11.5 Karus Therapeutics Limited
11.5.1 Karus Therapeutics Limited Company Details
11.5.2 Karus Therapeutics Limited Business Overview
11.5.3 Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Introduction
11.5.4 Karus Therapeutics Limited Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021)
11.5.5 Karus Therapeutics Limited Recent Development
11.6 ProQR Therapeutics N.V.
11.6.1 ProQR Therapeutics N.V. Company Details
11.6.2 ProQR Therapeutics N.V. Business Overview
11.6.3 ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Introduction
11.6.4 ProQR Therapeutics N.V. Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021)
11.6.5 ProQR Therapeutics N.V. Recent Development
11.7 RegeneRx Biopharmaceuticals, Inc.
11.7.1 RegeneRx Biopharmaceuticals, Inc. Company Details
11.7.2 RegeneRx Biopharmaceuticals, Inc. Business Overview
11.7.3 RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Introduction
11.7.4 RegeneRx Biopharmaceuticals, Inc. Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021)
11.7.5 RegeneRx Biopharmaceuticals, Inc. Recent Development
11.8 Scioderm, Inc.
11.8.1 Scioderm, Inc. Company Details
11.8.2 Scioderm, Inc. Business Overview
11.8.3 Scioderm, Inc. Epidermolysis Bullosa Therapeutics Introduction
11.8.4 Scioderm, Inc. Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021)
11.8.5 Scioderm, Inc. Recent Development
11.9 Stratatech Corporation
11.9.1 Stratatech Corporation Company Details
11.9.2 Stratatech Corporation Business Overview
11.9.3 Stratatech Corporation Epidermolysis Bullosa Therapeutics Introduction
11.9.4 Stratatech Corporation Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021)
11.9.5 Stratatech Corporation Recent Development
11.10 TWi Pharmaceuticals, Inc.
11.10.1 TWi Pharmaceuticals, Inc. Company Details
11.10.2 TWi Pharmaceuticals, Inc. Business Overview
11.10.3 TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Introduction
11.10.4 TWi Pharmaceuticals, Inc. Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021)
11.10.5 TWi Pharmaceuticals, Inc. Recent Development
11.11 WAVE Life Sciences Ltd.
11.11.1 WAVE Life Sciences Ltd. Company Details
11.11.2 WAVE Life Sciences Ltd. Business Overview
11.11.3 WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Introduction
11.11.4 WAVE Life Sciences Ltd. Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021)
11.11.5 WAVE Life Sciences Ltd. Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

...

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 表皮水疱症治療薬の世界市場規模・現状・予測2021年-2027年(Global Epidermolysis Bullosa Therapeutics Market Size, Status and Forecast 2021-2027)]についてメールでお問い合わせはこちらでお願いします。